Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Amgen and Allergan announce positive top-line results from comparative clinical study of ABP 798, biosimilar candidate to Rituxan® (rituximab)

worldpharmanewsAugust 23, 2019

Tag: Amgen , Allergan , ABP 798 , Rituxan

PharmaSources Customer Service